CPR Invest - Megatrends - R EUR - Acc ISIN : LU1734694380

CPR Invest - Megatrends - R EUR - Acc
R(C) - LU1734694380
Asset class: Equities

YTD
As of 17/11/2026
11.59%

Risk IndicatorThe level of risk of the fund mainly reflects the risk of the market in which the fund is invested and, as the case may be, the leveraging strategy or inverse performance of the index. The capital initially invested does not benefit from any guarantee. The current level of risk does not indicate the future level of risk and may change over time. The lowest risk level is not equal to a risk-free investment.
1234567
Lower Risk
Higher Risk
The risk indicator assumes you keep the product according to the holding period.

NAV
As of 18/11/2026
€190.87

SFDR ClassificationSustainable Finance Disclosure Regulation
Art. 8

Fund AUM
As of 18/11/2026
€272.73M
The investment objective is to outperform global equity markets over a long-term period (minimum of five years) by investing in equity funds or equities that benefit from global thematic trends.

NAVs

NAV from 14/12/2017 to 18/11/2026
Select period
Created with Highcharts 11.4.8CPR Invest - Megatrends - R EUR - AccJan '18Jul '18Jan '19Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '2675100125150175200225

Performance

Change in NAV in base 100
FundCPR Invest - Megatrends - R EUR - Acc (90.9% over the period)
Select period
Created with Highcharts 11.4.8CPR Invest - Megatrends - R EUR - AccBenchmarkJan '18Jul '18Jan '19Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '2650100150200250300
* Rolling performance : for funds that have been launched since less than 1 year or 3 years or 5 years, the performance showed in the table in the 1 year or 3 years or 5 years column is the performance since inception of the fund.

All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.

Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.

The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).

The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.
FundCPR Invest - Megatrends - R EUR - Acc (90.9% over the period)
Select period
Created with Highcharts 11.4.8CPR Invest - Megatrends - R EUR - AccBenchmarkJan '18Jul '18Jan '19Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '2650100150200250300
* Rolling performance : for funds that have been launched since less than 1 year or 3 years or 5 years, the performance showed in the table in the 1 year or 3 years or 5 years column is the performance since inception of the fund.

All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.

Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.

The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).

The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.

Portfolio Analysis

Repartition 10/31/2026
Created with Highcharts 11.4.8Values31.13​31.1311.33​11.339.19​9.198.53​8.537.32​7.326.67​6.673.56​3.563.39​3.392.63​2.632.62​2.622.02​2.021.47​1.47Portfolio0246810121416182022242628303234Information TechnologyHealth CareIndustrialsFinancialsConsumer DiscretionaryCommunication ServicesEnergyUnknownConsumer StaplesMaterialsUtilitiesReal EstateHighcharts.com

Management commentary

Effective date: 31/10/2026

The month of October 2026 was marked by a new surge in energy prices. Indeed, attacks on ships continued in the Strait of Hormuz, the Houthis claimed responsibility for strikes on several Saudi refineries, and Donald Trump hinted that U.S. strikes on Iran could resume after the midterm elections on November 3. As a result, the price of Brent crude rose by nearly 14% over the month, reaching $118 per barrel, its highest level in six months. The price of natural gas also increased sharply, reaching its highest level since the end of 2022. Another key event of the month was the sharp decline in technology stocks at the very end of the month, following disappointing earnings reports from Alphabet, Amazon, and Intel, which reignited doubts about the profitability of massive investments in AI.

The inflation indices published in October, covering the month of September, accelerated again due to energy prices. In the eurozone, headline inflation reached 3.8% compared to 3.2% in August, its highest level since September 2023, with the energy component rising by 18.8% year-on-year. Conversely, core inflation remained broadly stable at 2.5%. In the United States, headline inflation (CPI) rose from 3.4% to 3.7%, while core inflation climbed to 2.6%, slightly higher than expected. The September “core PCE” inflation came in at 3.1%.

Activity indicators continued to be solid. In the United States, Q3 GDP growth came in at 3.4% quarter-on-quarter annualized, above expectations, driven by consumer spending and business investment. However, after a strong report in August, the September employment report disappointed, with only 29,000 non-farm jobs created and an increase in the unemployment rate to 4.2%. In the eurozone, GDP grew by 0.4% in Q3, despite a surprise 0.1% contraction in France, but the composite PMI fell to 51.9 in October from 53.1 in September, well below expectations. In China, GDP growth came in at 4.5% year-on-year in Q3, but the economy remains highly unbalanced and household consumption very weak.

After September, the first month in history during which the ECB, the Fed, and the BoJ all raised their key rates, these three central banks all decided to leave their rates unchanged in October. The Fed maintained the fed funds target range at 3.75/4%, but two FOMC members (Lisa Cook and Beth Hammack) voted in favor of another hike. Kevin Warsh indicated that the September rate hike had begun to take effect and that the tightening of financial conditions was paving the way for a period of more sustainable growth and price stability. For its part, the BoJ left its main policy rate at 1.25% but opened the door to a hike in December. Finally, the ECB left its deposit rate at 2.50%, even though energy prices in Europe are now between the “adverse” and “severe” scenarios mentioned in September, fueling upside risks for inflation and downside risks for growth. The Council debated another rate hike but judged that uncertainties were still too high, while indicating that “the direction is quite clear” for all its members. For now, it does not see a substantial risk of second-round effects.

Despite the rise in oil prices, bond yields fell sharply over the month, benefiting from a flight to safe-haven assets at the end of the month and the central banks’ pause. The U.S. 10-year yield fell by nearly 40 bps to 4.90%, after briefly exceeding 5.30% during the month. The German 10-year yield dropped by about 25 bps over the month to 3.29%, returning to its end-August levels. In Japan, the 10-year yield fell back below 3%, to 2.77%, its lowest level in nearly three months. Finally, gold declined again, by about 6% over the month, to just over $3,875 an ounce, penalized by the prospect of further Fed rate hikes.

Equity markets were shaken at the end of the month by doubts over the profitability of AI-related investments. The S&P 500 fell by 0.9% over the month and the Nasdaq by more than 5%, while the Dow Jones rose by 1.7%. The Eurostoxx 600 was more resilient, with a gain of 1.9%. Asian markets, more exposed to the semiconductor sector, fell sharply: the Nikkei lost nearly 5.2% and the MSCI Emerging dropped 8.1%, its worst month since the start of the war in Iran.

 

On the thematic side, after several months dominated by large technology stocks and artificial intelligence, investors began to favor defensive sectors, undervalued stocks, and quality assets. The correction in AI-related stocks does not necessarily signal the end of the technology cycle, but rather reflects increased demands for profitability and financial discipline.

Investors are now questioning: the very high level of investment in AI infrastructure, the ability of hyperscalers to turn these investments into cash flow, the future profitability of data centers, and the debt levels of certain cloud specialists. The question is no longer just who will benefit from AI, but above all who will be able to sustainably capture its economic value.

October 2026 confirmed the role of the healthcare sector as a safe haven, and AI-driven drug discovery is emerging as a new strong thematic focus. The main challenge for investors lies in balancing the undeniable acceleration of drug discovery by AI and its still uncertain impact on clinical success—a distinction that is increasingly influencing stock selection within the sector.

Around consumer themes, quarterly reports showed that the preference for experiences over goods has intensified, with high-end travel and beauty remaining strong segments, while non-essential retail—especially in China and among low-income households globally—faced significant challenges. This K-shaped dynamic is the guiding thread for consumer brand positioning, favoring premium, good value-for-money, and experience-focused brands over mid-range and luxury brands.

In October, CPR Megatrends fell by 1.49% compared to +0.97% for its benchmark index, the MSCI World (EUR). This significant underperformance is the result of our strong exposure to the AI theme and mainly to AI infrastructure. We started the month with an overweight in the Technology sector of nearly 7%. In response to the sell-off in the theme, we completely reduced this exposure to return to neutral by the end of the month. In contrast, we gradually increased the healthcare sector by +3.5%, notably with exposure to the Biotechnology theme.

Characteristics

General data

Inception date
14/12/2017
First Nav Date
14/12/2017
Currency
EUR
Show more
Valuation
Daily
Minimum initial investment
1 10/1000° share(s)/equity
Minimum additional investment
1 10/1000° share(s)/equity

Costs Composition

One-off costs upon entry or exit (Investment EUR 10,000)If you exit after 1 year
Entry costsThis includes distribution costs of 5.00% of amount invested. This is the most you will be charged. The person selling you the product will inform you of the actual charge.Up to €500.00
Exit costsWe do not charge an exit fee for this product, but the person selling you the product may do so.€0.00
Ongoing costs taken each year (Investment EUR 10,000)
Management fees and other administrative or operating costs1.07% of the value of your investment per year. This percentage is based on actual costs over the last year.€101.18
Transaction costs0.13% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.€12.69
Incidental costs taken under specific conditions (Investment EUR 10,000)
Performance fees

15.00% annual outperformance of the reference asset 100% MSCI WORLD NR Close. The calculation applies on each Net Asset Value calculation date in accordance with the terms described in the prospectus. Past underperformances over the last 5 years should be clawed back before any new accrual of performance fee.The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.

The performance fee is paid even if the performance of the share over the performance observation period is negative, while remaining higher than the performance of the Reference Asset.

€0.00

Codification

ISIN code
LU1734694380
Bloomberg code
CPMEGRA LX
Reuters code
LP68460151

Investment Objective

The investment objective is to outperform global equity markets over a long-term period (minimum of five years) by investing in equity funds or equities that benefit from global thematic trends.

Documents

LanguageDocumentsTypeClosing Date
NL
PDF
04/11/2026
PDF
31/01/2026
EN
PDF
31/07/2025
PDF
01/10/2026
EN
PDF
31/10/2026
Prices expressed in a currency other than the base currency of the portfolio are available for information purposes only.
Nothing contained in this site constitutes a solicitation or offer by any member of the Amundi to provide any investment advice or service or to purchase or sell any financial instruments. The information it contains aims to inform the subscriber by providing information on the UCITS supplemental to that appearing in the Information Memorandum. The material provided on this site is presented as of the date shown and "as is". Amundi does not expressly or impliedly warrant the accuracy of the information provided on this site and expressly disclaims any warranties of fitness of this site for any particular purpose. This material reflects the opinion of the management company at the date of printing. The material is based upon information that we consider reliable, but we do not represent it is accurate, complete, valid or timely and it should not be relied on as such for any particular purpose. Any subscription should be based solely on the Information Memorandum provided to subscribers prior to the subscription and/or available upon request.
The collective inestment scheme (UCITS) has been recognised for public marketing in the Netherlands  by the Authority for The Financial Markets (AFM)